Devonian Health Group Inc. announced that the Corporation has filed a Patent Cooperation Treaty (PCT) patent application for seeking protection for thylakoids developed by the company such as Thykamine in wound healing. The filing of this PCT application will give the Corporation the option of seeking patent protection in about 157 PCT contracting states. The filing of this new patent application is a key component of broad strategy in expanding robust patent estate.

The patent application highlights the positive impact of thylakoids develop by the Corporation such as Thykamine on the wound healing cascade, for example, by increasing the production of collagen, Granulocyte Colony-Stimulating Factor and Granulocyte Macrophage Colony-Stimulating Factor. Importantly, this filing is timely as look to demonstrate the potential broad application of Thykamine as a therapeutic drug. Thykamine, the first pharmaceutical product issued from Devonian?s SUPREX platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders.

The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a Phase II clinical study in patients with mild-to-moderate atopic dermatitis.